B. Riley Research Analysts Lift Earnings Estimates for PDSB

PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Research analysts at B. Riley lifted their Q2 2025 earnings per share estimates for PDS Biotechnology in a report issued on Monday, May 19th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.23) per share for the quarter, up from their prior forecast of ($0.28). The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.20) per share. B. Riley also issued estimates for PDS Biotechnology's Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at $0.27 EPS.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04.

PDSB has been the subject of several other research reports. HC Wainwright reduced their price target on shares of PDS Biotechnology from $21.00 to $13.00 and set a "buy" rating for the company in a report on Thursday, March 27th. Wall Street Zen upgraded PDS Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday.

PDS Biotechnology Stock Down 5.7%

Shares of NASDAQ:PDSB traded down $0.09 during midday trading on Thursday, reaching $1.49. The company had a trading volume of 530,093 shares, compared to its average volume of 485,087. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The stock's fifty day moving average price is $1.23 and its 200-day moving average price is $1.53. The stock has a market capitalization of $68.11 million, a P/E ratio of -1.28 and a beta of 1.40. PDS Biotechnology has a one year low of $0.85 and a one year high of $4.42.

Hedge Funds Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in shares of PDS Biotechnology in the fourth quarter valued at about $26,000. Blair William & Co. IL grew its stake in PDS Biotechnology by 29.4% in the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company's stock valued at $257,000 after acquiring an additional 35,757 shares during the period. Virtu Financial LLC bought a new position in shares of PDS Biotechnology in the fourth quarter valued at approximately $89,000. Renaissance Technologies LLC lifted its holdings in PDS Biotechnology by 331.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock worth $163,000 after acquiring an additional 76,800 shares during the period. Finally, Marshall Wace LLP lifted its holdings in PDS Biotechnology by 38.4% during the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock worth $64,000 after acquiring an additional 10,837 shares during the period. Institutional investors and hedge funds own 26.84% of the company's stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.